Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer
1099.1000 -1.40 (-0.13%)
NSE Oct 23, 2025 15:31 PM
Volume: 885.6K
 

1099.10
-0.13%
ICICI Securities Limited
ICICI Securities Ltd | Retail Equity Research Revenues grew 11% YoY to | 3906 crore (I-direct estimate: | 3870 crore) on account of 12% growth in the US to | 1745 crore (I-direct estimate: | 1925 crore). Europe business grew 9% YoY to | 855 crore (I-direct estimates: | 772 crore) EBITDA margins declined 42 bps YoY to 22.9% (I-direct estimates: 24.5%) mainly on account of higher other expenses. EBITDA grew 9% to | 895 crore (I-direct estimate: | 948 crore)...
Number of FII/FPI investors decreased from 728 to 700 in Sep 2025 qtr
More from Aurobindo Pharma Ltd.
Recommended